As for patients with cancer of the cervix uteri, Monk et al. [23] showed that 1st line pembrolizumab + chemotherapy significantly improved the OS of patients with recurrent/metastatic cancer of the cervix uteri compared to that via chemotherapy alone, especially in patients showing positive programmed death-ligand 1 (PD-L1) status (median OS for all patients: 26.4 vs. 16.8 months, for PD-L1 positive patients; 28.6 vs. 16.5 months). This evidence concerns the gene CD274 and cervical cancer.